Roseburia spp. as Next Generation Probiotics

Interest in Roseburia spp. has increased with reports that the abundance of these bacteria is reduced in individuals affected by inflammatory diseases and colorectal cancer. Roseburia spp. play an important role in the control of gut inflammatory processes, amelioration of atherosclerosis, and the maturation of the immune system, primarily through the production of butyrate. They are the next generation probiotics as promising and potentially effective treatments. Creative Biolabs has been focusing on the research of next generation probiotics for more than 10 years and has accumulated profound experience in the development of live biotherapeutic products (LBP).

Introduction of Roseburia spp.

Roseburia spp., together with Faecalibacterium prausnitzii and Eubacterium rectale, constitute a group of dominant butyrate-producing Firmicutes, estimated to account for 7-24% of the total bacteria in the healthy human colon. Roseburia spp. belongs to the phylum Firmicutes, class Clostridia, order Clostridiales, and family Lachnospiraceae. The genus Roseburia consists of obligate Gram-positive anaerobic bacteria that are slightly curved, rod-shaped, and motile through multiple subterminal flagella. It has five well-characterized species (Roseburia intestinalis, Roseburia hominis, Roseburia inulinivorans, Roseburia faecis, and Roseburia cecicola), all of which produce short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate. Roseburia spp., due to its new role in regulating gut microbial ecology, immune response, and human disease development. has been brought to the front.

Roseburia intestinalis is found to be the bacteria that produced butyrate most in human faeces. Evidence suggests that this bacterium contributes to a variety of diseases, such as inflammatory bowel disease, type 2 diabetes, antiphospholipid syndrome, and atherosclerosis.

Roseburia hominis is a relatively newly recognized probiotic bacteria species. It can penetrate the mucus layer and stick to the surface of host intestinal epithelial cells, which promotes the probiotic potential of these gut bacteria.

Roseburia spp. for Disease Treatment

  • Alcohol-related Liver Diseases (ALDs)

When Roseburia spp. was used in ALD mouse models, liver steatosis and inflammation were significantly improved regardless of bacterial activity. R. intestinalis flagellin may be recognized by Toll-like receptor 5 (TLR5), restore intestinal barrier integrity by up-regulating tight junction protein Occludin, and help restore intestinal microbiota by up-regulating IL-22 and REG3g expression. The results suggested that Roseburia spp. can improve the intestinal ecosystem and prevent intestinal leakage, thereby improving ALDs.

Administration of<em>Roseburia spp.</em> ameliorates alcoholic fatty liver in mice. Fig.1 Administration ofRoseburia spp. ameliorates alcoholic fatty liver in mice. (Seo, 2020)

Autoimmune diseases often involve multiple systems, including the gut. Bacteria interact with enteric mucosal immune cells by presenting antigen and chemical signals to organs, such as the thymus, brain, liver, and pancreas. Scientists found a decreased Roseburia abundance, which was used to distinguish RA patients from the healthy group in a random forest classification model. In addition, Roseburia genus is a potential health marker because of its butyrate-producing and anti-inflammatory properties. Notably, identical lower gut Roseburia abundance phenomena were found in adults with Behc.et syndrome and systemic sclerosis.

Metabolic diseases are typically multi-nutrition utilizing disorders and abnormalities of immune-induced hormones. Roseburia spp. is a critical butyrate-producing bacteria cluster. Butyrate can increase energy expenditure and lipid oxidation, which affects energy homeostasis and lipid metabolism. In the future, Roseburia spp. will be included in probiotic prescriptions to treat metabolic disorders.

<em>Roseburia</em> dysbiosis-associated diseases exist in different systems. Fig.2 Roseburia dysbiosis-associated diseases exist in different systems. (Nie, 2021)

Creative Biolabs’ goal is to commercialize its proprietary technology to provide researchers with a full range of LBP development services in the next generation probiotics industry. We have the expertise to optimize each stage to ensure you get your desired outcome. If you are interested in our Roseburia spp. related services or products, please feel free to contact us for details.

References

  1. Seo, B.; et al. Roseburia spp. abundance associates with alcohol consumption in humans and its administration ameliorates alcoholic fatty liver in mice. Cell Host & Microbe. 2020, 27(1): 25-40. e6.
  2. Nie, K.; et al. Roseburia intestinalis: A Beneficial Gut Organism From the Discoveries in Genus and Species. Frontiers in cellular and infection microbiology. 2021: 1147.

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Live Biotherapeutics Drug Discovery

Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Contact us

Contact us

Copyright © 2022 Creative Biolabs. All Rights Reserved.

Inquiry Basket